Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Amgen's Phase 2 study evaluating the safety and efficacy of VIB4920 in rheumatoid arthritis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• VIB4920 (VIB4920)

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2023-02-14